首页> 外文期刊>HPB Surgery >Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged Recurrence-Free Survival of Progressed Hepatocellular Carcinoma Patients after Hepatic Resection
【24h】

Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged Recurrence-Free Survival of Progressed Hepatocellular Carcinoma Patients after Hepatic Resection

机译:术前放牛酸增强MRI和同时治疗早期肝细胞癌进展期肝细胞癌患者肝切除术后无复发生存时间延长

获取原文
       

摘要

Background/Purpose. The purpose of this study was to clarify whether preoperative gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) and simultaneous treatment of suspected early hepatocellular carcinoma (eHCC) at the time of resection for progressed HCC affected patient prognosis following hepatic resection.Methods. A total of 147 consecutive patients who underwent their first curative hepatic resection for progressed HCC were enrolled. Of these, 77 patients underwent EOB-MRI (EOB-MRI (+)) before hepatic resection and the remaining 70 patients did not (EOB-MRI (−)). Suspected eHCCs detected by preoperative imaging were resected or ablated at the time of resection for progressed HCC.Results. The number of patients who underwent treatment for eHCCs was significantly higher in the EOB-MRI (+) than in the EOB-MRI (−) (17 versus 6;P=0.04). Recurrence-free survival (1-, 3-, and 5-year; 81.4, 62.6, 48.7% versus 82.1, 41.5, 25.5%, resp.,P<0.01), but not overall survival (1-, 3-, and 5-year; 98.7, 90.7, 80.8% versus 97.0, 86.3, 72.4%, resp.,P=0.38), was significantly better in the EOB-MRI (+). Univariate and multivariate analyses showed that preoperative EOB-MRI was one of the independent factors significantly correlated with better recurrence-free survival.Conclusions. Preoperative EOB-MRI and simultaneous treatment of eHCC prolonged recurrence-free survival after hepatic resection.
机译:背景/目的。这项研究的目的是弄清术前使用gadoxetic acid增强磁共振成像(EOB-MRI)和同时怀疑可切除的早期肝细胞癌(eHCC)的进展性肝癌切除是否同时影响了肝切除术后患者的预后。总共纳入了147例因肝癌进展而进行首次根治性肝切除的患者。其中,有77例患者在肝切除之前接受了EOB-MRI(EOB-MRI(+))治疗,其余70例未进行(EOB-MRI(-))。术前影像学检查发现可疑的eHCCs在切除时被切除或消融,以进行进展的HCC。在EOB-MRI(+)中接受eHCC治疗的患者数量明显高于EOB-MRI(-)(17比6; P = 0.04)。无复发生存期(1、3和5年; 81.4、62.6、48.7%与82.1、41.5、25.5%,相对,P <0.01),但无总生存期(1、3和3) 5年; 98.7、90.7、80.8%与97.0、86.3、72.4%,分别为P = 0.38),在EOB-MRI中显着更好(+)。单因素和多因素分析表明,术前EOB-MRI是与更好的无复发生存率显着相关的独立因素之一。术前EOB-MRI和同时治疗eHCC可延长肝切除术后的无复发生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号